Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms
Cancer Immunology, Immunotherapy · 15.07.2025 · 74 (8)
DOI: 10.1007/s00262-025-04128-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 15.07.2025. Verfasst von Erin C Sundstrom und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Rd, Unit 3092, Storrs, CT, 06269, USA. Hauptthemen laut MEDLINE: Receptors, Immunologic, Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Association of Immunologists Careers in Immunology Fellowship Program.
Abstract (Originalsprache)
TIGIT (T cell immunoreceptor with Ig and ITIM domains) has garnered interest as a next-generation anti-cancer immunotherapy target, yet its development has been marred by recent clinical failures. This review explores clinical and preclinical studies on TIGIT, examining antibody therapies, co-targeting with other checkpoint inhibitors, mechanistic signaling models, and the role of the Fc region. Here, we discuss how preclinical studies have found antitumor effects from anti-TIGIT antibodies, in particular when using the Fc competent mIgG2 scaffold in combination with anti-PD-1 in smaller-sized tumors. Yet, human monotherapy trials with IgG1 anti-TIGIT have disappointed. We investigate the extent to which combining anti-TIGIT with other treatments (primarily anti-PD-1) improves effectiveness, showing a clear benefit to co-targeting TIGIT, especially in patients positive for PD-L1 expression. We also discuss the Fc region, which has been thought to enhance success through mechanisms like myeloid cell activation, DC modification, and/or Treg depletion, but also risks targeting exhausted T cells for destruction, rather than activating them. The current evidence supports that TIGIT remains an interesting target, especially in Fc silent format, but expectations should be tempered, and research should focus on TIGIT blockade in combination with PD-1 blockade and how to best apply this combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Rd, Unit 3092, Storrs, CT, 06269, USA.
- Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
- Department of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Rd, Unit 3092, Storrs, CT, 06269, USA. andrew.wiemer@uconn.edu.
- Institute for Systems Genomics, University of Connecticut, Storrs, CT, 06269, USA. andrew.wiemer@uconn.edu.
Förderung
- American Association of Immunologists Careers in Immunology Fellowship Program
Zitieren
APA
Sundstrom, E. C., Huang, X., & Wiemer, A. J. (2025). Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms. Cancer Immunology, Immunotherapy, 74(8). https://doi.org/10.1007/s00262-025-04128-7
Vancouver
Sundstrom EC, Huang X, Wiemer AJ. Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms. Cancer Immunology, Immunotherapy. 2025;74(8). doi:10.1007/s00262-025-04128-7
BibTeX
@article{Sundstrom2025,
author = {Sundstrom, Erin C and Huang, Xueting and Wiemer, Andrew J},
title = {Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {8},
doi = {10.1007/s00262-025-04128-7}
}
EUVIMED